A greater sensitivity to cisplatin with decreased BRCA1 mRNA expression and a greater resistance to the paclitaxel with increased BRCA1 mRNA expression was observed in breast cancer cell lines [7,8]. This evidence concerns the gene BRCA1 and breast carcinoma.